Nephrology · KIMS Secunderabad
Contrast Nephropathy — Kidney Injury After Contrast Dye: Risk, Prevention, and Management
Contrast-induced nephropathy (CIN) — also termed contrast-induced acute kidney injury (CI-AKI) — is a deterioration in kidney function occurring within 24 to 72 hours of administration of iodinated contrast media used for CT scans, coronary angiography, and other radiological procedures. It is defined as a rise in serum creatinine of 44 µmol/L (0.5 mg/dL) or more, or a 25% increase from baseline, within 48 to 72 hours of contrast exposure, in the absence of another cause. It is the third most common cause of hospital-acquired AKI after reduced perfusion and nephrotoxic drugs.
The true incidence of CIN has been significantly revised downward in recent years — large population studies have shown that many apparent cases of post-contrast AKI in hospitalised patients would have developed AKI anyway from their underlying illness, independent of contrast. In patients with normal kidney function (eGFR above 60 ml/min/1.73m²) and no diabetes, the risk of genuine contrast-induced AKI is now considered very low — below 1%. The risk rises substantially in patients with pre-existing CKD, diabetes, and multiple risk factors.
Risk factors — who is at highest risk
CKD (eGFR below 45 ml/min)
The single most important risk factor. Risk rises sharply as eGFR falls. Below 30 ml/min — highest risk category.
Diabetes mellitus with CKD
Diabetic nephropathy markedly amplifies contrast risk — reduced renal prostaglandins and endothelial dysfunction impair the adaptive response.
Haemodynamic instability / dehydration
Reduced effective circulating volume intensifies renal vasoconstriction from contrast. Adequate pre-hydration is the most important preventive measure.
High contrast volume
Risk increases with contrast volume. Using the minimum effective volume reduces risk. CT protocols can be adapted to reduce dose.
Nephrotoxic medications
NSAIDs (reduce prostaglandin-mediated vasodilation), aminoglycosides, and diuretics should be withheld 24–48 hours before elective high-risk contrast procedures.
Multiple contrast exposures in 72 hours
Contrast should not be given twice within 72 hours unless essential — repeated exposure before the kidney recovers from the first exposure amplifies risk.
Heart failure, myeloma
Heart failure reduces renal perfusion; myeloma light chains sensitise tubular cells to contrast toxicity.
Prevention — the most important management step
IV hydration — the single most evidence-based preventive measure
IV 0.9% normal saline or isotonic sodium bicarbonate solution (1 to 1.5 ml/kg/hour) administered for 3 to 12 hours before and 6 to 12 hours after contrast administration. This maintains renal tubular flow, dilutes contrast concentration in the tubules, and counters the vasoconstriction that contrast causes. For elective high-risk procedures at KIMS, pre-hydration is administered the morning of the procedure. For emergency procedures, more compressed hydration protocols are used.
N-acetylcysteine (NAC) — controversial but widely used
Oral NAC (600mg twice daily for 2 days surrounding the contrast procedure) was historically recommended for CIN prevention. The PRESERVE trial (2018) showed no benefit over IV hydration alone. NAC is inexpensive and safe — it continues to be used at KIMS as an adjunct in very high-risk patients, though it is not relied upon as the primary preventive strategy.
Use low- or iso-osmolar contrast
Non-ionic low-osmolar contrast media (iohexol, iopamidol) and iso-osmolar contrast (iodixanol) cause significantly less renal vasoconstriction than older high-osmolar ionic agents. All contrast used at KIMS is low- or iso-osmolar.
Withhold nephrotoxic medications
NSAIDs and aminoglycosides are withheld 24 to 48 hours before elective contrast procedures in high-risk patients. Metformin is withheld for 48 hours after contrast administration in patients with eGFR below 45 ml/min (metformin is not nephrotoxic itself — but if CIN occurs and creatinine rises, metformin accumulates and risks lactic acidosis).
Consider alternative imaging
For patients at very high risk of CIN (eGFR below 30 ml/min), the necessity of contrast CT should be reviewed — does the diagnostic question require contrast? Can ultrasound, MRI (with gadolinium — which carries its own risk in very low eGFR patients), or non-contrast CT answer the question? At KIMS, the radiology and nephrology teams jointly review imaging requests for very high-risk patients.
Management if CIN occurs
CIN is managed supportively — no specific antidote exists. Management: stop nephrotoxic medications, maintain adequate hydration (IV fluids), monitor creatinine and electrolytes daily, watch for hyperkalaemia and fluid overload, and initiate dialysis if AKI becomes severe. Most CIN is mild and self-limiting — creatinine peaks at 3 to 5 days and returns to baseline by 7 to 14 days. Severe, dialysis-requiring CIN is uncommon in patients without pre-existing severe CKD.
Speak to a KIMS Nephrologist Before Your Contrast CT or Cardiac Catheterisation
Frequently Asked Questions — Contrast Nephropathy
It depends on the degree of kidney disease and the clinical urgency. For patients with eGFR above 45 ml/min and no diabetes, the risk of contrast-induced AKI is low and contrast CT can generally proceed with standard pre-hydration. For eGFR 30 to 45 ml/min, the risk is moderate — adequate pre-hydration, minimum contrast volume, low-osmolar contrast, and avoiding concomitant nephrotoxins reduce the risk. For eGFR below 30 ml/min, the risk is highest — the decision requires a risk-benefit discussion between the requesting clinician, the radiologist, and the nephrologist. At KIMS, patients referred for contrast CT with known CKD are reviewed by the nephrology team before the procedure if eGFR is below 45 ml/min.
No — non-contrast CT (CT without IV contrast injection) does not carry a risk of contrast nephropathy. The iodinated contrast agent, not the X-ray itself, is responsible for the kidney risk. Non-contrast CT can detect many conditions — kidney stones (the most common indication for non-contrast CT KUB), bone lesions, some abdominal emergencies — without any nephrotoxic risk. When contrast is required but the risk is high, a non-contrast CT may provide sufficient diagnostic information for the immediate clinical question.
In patients with eGFR below 45 ml/min, metformin should be withheld for 48 hours after contrast administration. Metformin itself is not nephrotoxic — but if contrast nephropathy occurs and creatinine rises, metformin accumulates (because it is renally excreted) and increases the risk of lactic acidosis. In patients with eGFR above 45 ml/min and no other risk factors, the risk of CIN is very low and the risk of metformin-associated lactic acidosis is correspondingly low — withholding metformin is at the clinician's discretion. For elective high-risk procedures, metformin is withheld from the day of the procedure until creatinine is confirmed stable at 48 hours.
Oral hydration helps but is less effective and less reliable than IV hydration for preventing CIN. Oral fluids are absorbed variably — particularly in patients who are unwell or nil-by-mouth. IV isotonic saline provides controlled, predictable volume expansion that is not possible with oral fluids alone. For low-risk patients having outpatient contrast CT, oral hydration (1 to 1.5 litres of water in the 2 to 4 hours before the procedure) is a reasonable and practical approach. For high-risk patients with CKD, IV hydration before and after the procedure is the standard of care.
KIMS Secunderabad — Dr. E. Ravi (Senior Consultant Nephrologist), pre-contrast nephrology review for high-risk patients (eGFR below 45 ml/min), IV hydration protocol, low-osmolar contrast use, minimum contrast volume protocols, 24-hour creatinine monitoring post-procedure. NABH and NABL accredited. Call 040-4488-5000.